No human clinical trial data quantifies the precise acceleration rate in humans, and the direct translation of the 30% to 50% figure from rodent models to human tendon repair remains unconfirmed by controlled clinical research
Investigators use this higher-concentration formulation to evaluate prolonged receptor-crosstalk efficiency and metabolic homeostasis, rather than clinical efficacy, therapeutic outcomes, or disease treatment
Energy levels may fluctuate initially but generally stabilize or improve as metabolic health optimizes
Conflict of interest ES has served as speaker for Abbvie, Agave, AGPharma, Alfasigma, Aurora Pharma, CaDiGroup, Celltrion, Dr Falk, EG Stada Group, Fenix Pharma, Fresenius Kabi, Galapagos, Janssen, JB Pharmaceuticals, Innovamedica/Adacyte, Malesci, MayolyBiohealth, Omega Pharma, Pfizer, Reckitt Benckiser, Sandoz, SILA, Sofar, Takeda, Tillots, Unifarco